Evidence map›Paper›PMID 19788744›Full record

ArticleVirology journal2009

Identification of novel host-oriented targets for Human Immunodeficiency Virus type 1 using Random Homozygous Gene Perturbation.

Hanwen Mao, Hanson Chen, Zena Fesseha, Shaojing Chang, Huong Ung-Medoff, Jessica Van Dyke, Manu Kohli, Wu-Bo Li, Michael Goldblatt, Michael S Kinch

Abstract read
In one paragraph

Article in Virology journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Compound FC-10696 Inhibits Egress of Marburg Virus.Antimicrobial agents and chemotherapy · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hanwen MaoFunctional Genetics, Inc, Gaithersburg, MD 20878, USA. hmao@functional-genetics.com
Hanson Chen
Zena Fesseha
Shaojing Chang
Huong Ung-Medoff
Jessica Van Dyke
Manu Kohli
Wu-Bo Li
Michael Goldblatt
Michael S Kinch

Funding

Discovery of Critical Host Genes Enabling Resistance to HIV-1 Infection as TherapR43AI074484 · NIAID · FUNCTIONAL GENETICS, INC. · PI MAO, HANWEN · 2007 to 2008
$599k
NIAID NIH HHS 1R43 AI074484-01NIAID NIH HHS R43 AI074484
6 · The paper itself

Abstract

backgroundHuman Immunodeficiency Virus (HIV) is a global threat to public health. Current therapies that directly target the virus often are rendered ineffective due to the emergence of drug-resistant viral variants. An emerging concept to combat drug resistance is the idea of targeting host mechanisms that are essential for the propagation of the virus, but have a minimal cellular effect.

resultsHerein, using Random Homozygous Gene Perturbation (RHGP), we have identified cellular targets that allow human MT4 cells to survive otherwise lethal infection by a wild type HIV-1NL4-3. These gene targets were validated by the reversibility of the RHGP technology, which confirmed that the RHGP itself was responsible for the resistance to HIV-1 infection. We further confirmed by siRNA knockdowns that the RHGP-identified cellular pathways are responsible for resistance to infection by either CXCR4 or CCR5 tropic HIV-1 variants. We also demonstrated that cell clones with these gene targets disrupted by RHGP were not permissible to the replication of a drug resistant HIV-1 mutant.

conclusionThese studies demonstrate the power of RHGP to identify novel host targets that are essential for the viral life cycle but which can be safely perturbed without overt cytotoxicity. These findings suggest opportunities for the future development of host-oriented therapeutics with the broad spectrum potential for safe and effective inhibition of HIV infection.

Indexed as

Host-Pathogen InteractionsVirus ReplicationCell LineCell SurvivalGene Knockdown TechniquesHIV-1HumansImmunity, InnateMutagenesis, InsertionalRNA, Small InterferingRNA, Small Interfering

Identifiers

PMID19788744
PMCPMC2760863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.